At the cutting edge between differentiation and proliferation control, mTOR inhibitors promote in the experimental setting translation, particularly of frequently available oncoproteins, like cMyc, cyclinD1, ornithine decarboxylase (ODC), vascular endothelial growth factor (VEGF), fibroblast growth factors (FGF), hypoxia-inducible Factor 1α (HIF1α) and myeloid cell leukemia sequence 1 (Mcl-1) and shift cancer cell phenotypes to cancer stem cell characteristics (29). This evidence concerns the gene MTOR and cancer.